[1]张海福 张邢炜.血液透析患者冠状动脉介入治疗术后双联抗血小板治疗的进展[J].心血管病学进展,2020,(12):1281-1284.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.014]
　ZHANG Haifu,ZHANG Xingwei.Dual Antiplatelet Therapy after Coronary Intervention in Hemodialysis Patients[J].Advances in Cardiovascular Diseases,2020,(12):1281-1284.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.014]
点击复制

血液透析患者冠状动脉介入治疗术后双联抗血小板治疗的进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年12期
页码:
1281-1284
栏目:
综述
出版日期:
2020-12-25

文章信息/Info

Title:
Dual Antiplatelet Therapy after Coronary Intervention in Hemodialysis Patients
作者:
张海福 张邢炜
(杭州师范大学附属医院心血管内科 杭州师范大学医学院,浙江 杭州310015)
Author(s):
ZHANG Haifu;  ZHANG Xingwei
(Department of Cardiology, The Affiliated Hospital of Hangzhou Normal University, School of Medicine, Hangzhou Normal University, Hangzhou 310015, Zhejiang, China)
关键词:
终末期肾脏病; 血液透析; 冠状动脉介入治疗; 双联抗血小板治疗
Keywords:
End-stage renal disease;  Hemodialysis;  Coronary intervention;  Dual antiplatelet therapy
DOI:
10.16806/j.cnki.issn.1004-3934.2020.12.014
摘要:
终末期肾脏病血液透析患者冠状动脉粥样硬化性心脏病的发病率和死亡率均高于一般人群。随着经皮冠脉介入治疗（PCI）技术的进展，越来越多的血液透析患者选择PCI干预冠状动脉缺血性疾病，但血液透析患者表现出较高血栓栓塞风险以及出血倾向，使得PCI术后双联抗血小板治疗方案无明确的定论。故本文将对血液透析患者PCI术后常用双联抗血小板治疗方案以及持续时间进行系统综述。
Abstract:
The morbidity and mortality of coronary atherosclerotic heart disease in patients with end-stage renal disease (ESRD) on hemodialysis were higher than that of the general population. With the development of percutaneous coronary intervention (PCI) technology,more and more hemodialysis patients choose PCI to intervene in coronary artery ischemic disease,but hemodialysis patients show a higher risk of thromboembolism and bleeding tendency,so there is no clear conclusion on dual antiplatelet therapy (DAPT) after PCI. Therefore,this article will systematically review the DAPT schemes and duration of hemodialysis patients after PCI.

参考文献/References:

[1].Schmidli J,Widmer MK,Basile C,et al. Editor’s choice-vascular access:2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)[J]. Eur J Vasc Endovasc Surg,2018,55(6):757-818.
[2].Li H,Feng SJ,Su LL,et al. Serum hepcidin predicts uremic accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy[J]. Chin Med J (Engl),2015,128(10):1351-1357.
[3].Covic A,Genovesi S,Rossignol P,et al. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations[J]. BMC Med,2018,16(1):158.
[4].Summaria F,Giannico MB,Talarico GP,et al. Antiplatelet therapy in hemodialysis patients undergoing percutaneous coronary interventions[J]. Nephrourol Mon,2015,7(4):e28099.
[5].Rios DRA,Carvalho MDG,Lwaleed BA,et al. Hemostatic changes in patients with end stage renal disease undergoing hemodialysis[J]. Clin Chim Acta,2010,411(3-4):135-139.
[6].Sood M M,Larkina M,Thumma J R,et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis:results from the DOPPS[J]. Kidney Int,2013,84(3):600-608.
[7].Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165.
[8].Guo LZ,Kim MH,Shim CH,et al. Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting[J]. Eur Heart J Cardiovasc Pharmacother,2016,2(3):145-151.
[9].Fu DL,Zhao TT,Peng WH,et al. Effect of dialysis on antiplatelet drug efficacy in uremic patients with coronary heart disease[J]. Chin Med J (Engl),2017,130(16):1914-1918.
[10].Guo LZ,Kim MH,Kim TH,et al. Comparison of three tests to distinguish platelet reactivity in patients with renal impairment during dual antiplatelet therapy[J]. Nephron,2016,132(3):191-197.
[11].Gremmel T,Müller M,Steiner S,et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy[J]. Nephrol Dial Transplant,2013,28(8):2116-2122.
[12].Amador-Martínez I,Pérez-Villalva R,Uribe N,et al. Reduced endothelial nitric oxide synthase activation contributes to cardiovascular injury during chronic kidney disease progression[J]. Am J Physiol Renal Physiol,2019,317(2):F275-F285.
[13].Chang TI,Montez-Rath ME,Tsai TT,et al. Drug-eluting versus bare-metal stents during PCI in patients with end-stage renal disease on dialysis[J]. J Am Coll Cardiol,2016,67(12):1459-1469.
[14].Asami M,Aoki J,Sato T,et al. Impact of stent type and prolonged dual antiplatelet therapy on long-term clinical outcomes in hemodialysis patients with coronary artery disease[J]. Cardiovasc Interv Ther,2018,33(1):84-94.
[15].Gasior P,Gierlotka M,Szczurek-Katanski K,et al. Biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in the diabetic population[J]. Cardiol J,2020. DOI:10.5603/CJ.a2019.0111.
[16].王耿,马蕊,韩雅玲,等. 聚合物可降解支架对维持性血液透析合并急性冠状动脉综合征患者的疗效[J]. 中国介入心脏病学杂志,2014(10):613-616.
[17].Zhang L,Li Y,Jing QM,et al. Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation:insights from the CREATE study[J]. J Interv Cardiol,2014,27(2):119-126.
[18].沈鑫,敖强国,程庆砾,等. 慢性肾脏病5期高龄男性患者出血危险因素及预后分析[J]. 中华医学杂志,2017,97(18):1420-1424.
[19].Chen YT,Chen HT,Hsu CY,et al. Dual Antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis[J]. Clin J Am Soc Nephrol,2017,12(2):262-271.
[20].Brieger D,Pocock SJ,Blankenberg S,et al. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries[J]. Int J Cardiol,2020,311:7-14.
[21].Nakamura M,Kimura K,Kimura T,et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease[J]. Circ J,2020,84(5):831-865.
[22].Jain N,Hunt S L,Cui H,et al. Trends for and clinical factors associated with choice of oral P2Y12 inhibitors for patients on chronic dialysis[J]. Cardiovasc Drugs Ther,2019,33(5):511-521.
[23].Kamada T,Iwasaki M,Konishi A,et al. A pharmacodynamics comparison of prasugrel and clopidogrel in patients undergoing hemodialysis[J]. Heart Vessels,2019,34(6):883-887.
[24].Tanios BY,Itani HS,Zimmerman DL. Clopidogrel use in end-stage kidney disease[J]. Semin Dial,2015,28(3):276-281.
[25].Htun P,Kan T,Mueller E,et al. Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study[J]. Thromb Haemost,2014,111(4):662-669.
[26].Chen CY,Lee KT,Lee CT,et al. Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis[J]. Int J Stroke,2014,9(5):580-590.
[27].Nishi T,Ariyoshi N,Nakayama T,et al. Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrel in Japanese patients[J]. J Cardiol,2017,69(5):752-755.
[28].Alexopoulos D,Panagiotou A,Xanthopoulou I,et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity[J]. J Thromb Haemost,2011,9(12):2379-2385.
[29].Ohno Y,Kitahara H,Fujii K,et al. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis[J]. J Cardiol,2019,73(1):51-57.
[30].Jeong KH,Cho JH,Woo JS,et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis:a randomized crossover study[J]. Am J Kidney Dis,2015,65(6):916-924.
[31].Kim JS,Woo JS,Kim JB,et al. The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis[J]. Int J Cardiol,2017,238:110-116.
[32].Lee CH,Tsai TH,Lin CJ,et al. Efficacy and safety of ticagrelor compared with clopidogrel in patients with end-stage renal disease with acute myocardial infarction[J]. Am J Cardiovasc Drugs,2019,19(3):325-334.
[33].James S,Budaj A,Aylward P,et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function:results from the Platelet Inhibition and Patient Outcomes (PLATO) trial[J]. Circulation,2010,122(11):1056-1067.
[34].Wang Z,Gong Y,Fan F,et al. Coronary artery bypass grafting vs. drug-eluting stent implantation in patients with end-stage renal disease requiring dialysis[J]. Ren Fail,2020,42(1):107-112.
[35].葛香妍,王耿,曹宁,等. 经皮冠状动脉介入治疗维持性血液透析合并急性冠脉综合征疗效观察[J]. 临床军医杂志,2016(5):488-491.
[36].Tanaka M,Moniwa N,Ohnishi H,et al. Impact of the number of anti-thrombosis agents in hemodialysis patients:BOREAS-HD2 Study[J]. Kidney Blood Press Res,2017,42(3):553-564.

相似文献/References:

[1]张琼月 甘华.血液透析患者发生心脏性猝死的易患因素[J].心血管病学进展,2020,(7):738.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.016]
　ZHANG Qiongyue,GAN Hua.Risk Factors for Sudden Cardiac Death in Hemodialysis Patients[J].Advances in Cardiovascular Diseases,2020,(12):738.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.016]
[2]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
　WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(12):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
[3]杜明亮 王泊然 惠慧 郑晓群.维持血液透析合并冠心病的患者降脂治疗的研究进展[J].心血管病学进展,2023,(12):1084.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.007]
　DU Mingliang,WANG Boran,HUI Hui,et al.Lipid-Lowering Therapy in Maintenance Hemodialysis Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2023,(12):1084.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.007]

备注/Memo

备注/Memo:
基金项目：浙江省中医药管理局项目（2019ZA093）
通信作者：张邢炜，E-mail:xwzhang@hznu.edu.cn
更新日期/Last Update: 2021-02-22